4//SEC Filing
KARSEN PERRY A 4
Accession 0001640455-23-000111
CIK 0001640455other
Filed
May 3, 8:00 PM ET
Accepted
May 4, 7:44 AM ET
Size
20.6 KB
Accession
0001640455-23-000111
Insider Transaction Report
Form 4
KARSEN PERRY A
Director
Transactions
- Disposition from Tender
Common Stock
2023-05-03−5,000→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2023-05-03−16,260→ 0 totalExercise: $9.56→ Common Stock (16,260 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-05-03−13,350→ 0 totalExercise: $7.92→ Common Stock (13,350 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-05-03−15,700→ 0 totalExercise: $7.58→ Common Stock (15,700 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-05-03−15,700→ 0 totalExercise: $7.27→ Common Stock (15,700 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-05-03−75,880→ 0 totalExercise: $4.06→ Common Stock (75,880 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-05-03−15,700→ 0 totalExercise: $4.46→ Common Stock (15,700 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-05-03−20,000→ 0 totalExercise: $2.80→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time").
- [F2]Pursuant to the terms of the merger agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.85 in cash (the "Offer Price") without interest and subject to applicable withholding taxes and (ii) one contingent value right.
- [F3]Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.
Documents
Issuer
Jounce Therapeutics, Inc.
CIK 0001640455
Entity typeother
Related Parties
1- filerCIK 0001260573
Filing Metadata
- Form type
- 4
- Filed
- May 3, 8:00 PM ET
- Accepted
- May 4, 7:44 AM ET
- Size
- 20.6 KB